P-0166 - Bevacizumab in Moroccan patients with metastatic colorectal cancer

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Mohammed El Fadli
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors M. El Fadli1, H. Alaoui Mhamdi1, N. Ismaili1, R. Belbaraka2
  • 1CHU Mohamed 6, Marrakech/MA
  • 2Medical Oncology, Centre Oncology Hematology, CHU Mohamed VI, FMPM, Marrakech/MA



Bevacizumab is a monoclonal antibody against vascular endothelial growth factor, has improves significantly progression free and/ or overall survival in metastatic colorectal cancer with standard chemotherapy. The aim of our study to evaluate efficacy and safety in Moroccan patients.


All patients with histologically proven metastatic colorectal cancer treated by bevacizumab in association with standard chemotherapy at oncology center in Mohamed VI university hospital of Marrakech in Morocco between October 2011 and December 2013 were included in a retrospective investigation. Efficacy was based on the evaluation of overall response rate (ORR = CR [complete response] + PR [partial response]) by using the RECIST criteria and safety was evaluated according to the NCT-CTC classification.


Eighty patients with metastatic cancers were included in our study. In a preliminary analysis we investigate the data of 52 patients. The ORR (CR + PR) was 65.2%. CR was observed in 2 cases (5.2%) while PR was observed in 60% of the cases. Three serious adverse events (grade 3 or 4) (5.7%) were registered; two cases of gastro-intestinales perforations (3.8%) and one case of hemorrage (1.9%). Hypertension was the most frequent adverse event (18.7%), followed by proteinuria (12.5%).


Our experience confirms the efficacy of bevacizumab in the treatment of metastatic colorectal cancer patients with a good safety profile.